Precigen Inc (PGEN) Stock Analysis

Precigen Inc (PGEN) is a publicly traded company in the HEALTHCARE sector. It trades at $3.86, carries a market capitalization of $1.47B. This page summarizes the public market data, fundamentals, and frequently asked questions for PGEN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Precigen Inc currently has a Bullish sentiment score of 0.17.

About Precigen Inc

Precigen Inc (PGEN) is an innovative biotechnology company based in Germantown, Maryland, dedicated to the advancement of next-generation cell and gene therapies. By utilizing its proprietary technologies, Precigen is revolutionizing treatment approaches for cancer and autoimmune diseases, aiming to enhance patient outcomes through therapies that effectively engage the immune system. With a robust pipeline and a commitment to scientific excellence, the company is positioned to become a leader...

GNG Research Analysis

GNG Research scores Precigen Inc (PGEN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PGEN.

Frequently Asked Questions

Does PGEN pay dividends?

Precigen Inc (PGEN) does not currently pay a regular dividend.

What is PGEN's market cap?

Precigen Inc (PGEN) has a market capitalization of $1.47B with a current stock price of $3.86.